Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

被引：13
|
作者：
Devlies, Wout [1 ,2 ]
Eckstein, Markus [3 ]
Cimadamore, Alessia [4 ]
Devos, Gaetan [1 ]
Moris, Lisa [1 ,2 ]
van den Broeck, Thomas [1 ]
Montironi, Rodolfo [4 ]
Joniau, Steven [1 ]
Claessens, Frank [2 ]
Gevaert, Thomas [5 ]
机构：
[1] Univ Hosp Leuven, Dept Urol, B-3000 Leuven, Belgium
[2] Katholieke Univ Leuven, Lab Mol Endocrinol, B-3000 Leuven, Belgium
[3] Friedrich Alexander Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany
[4] Polytech Univ theMarche Reg, United Hosp, Sch Med, Sect Pathol Anat, I-60121 Ancona, Italy
[5] Univ Hosp Leuven, Dept Pathol, B-3000 Leuven, Belgium
来源：
CELLS | 2020年 / 9卷 / 11期
关键词：
prostate cancer; biomarker; targeted therapies; histology; mCRPC; androgen receptor; ANDROGEN-DEPRIVATION THERAPY; CIRCULATING TUMOR-CELLS; POZ PROTEIN SPOP; EMERGING MECHANISMS; RECEPTOR; EXPRESSION; MUTATIONS; GENE; TMPRSS2-ERG; INHIBITORS;
D O I：
10.3390/cells9112494
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
引用
收藏
页码：1 / 13
页数：13
相关论文
共 50 条
  • [1] Clinical implications of the 5α-androstanedione pathway for castration-resistant prostate cancer
    Sharifi, Nima
    FUTURE ONCOLOGY, 2011, 7 (11) : 1239 - 1241
  • [2] The changing landscape in metastatic castration-resistant prostate cancer
    Leibowitz-Amit, Raya
    Joshua, Anthony M.
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2013, 7 (03) : 243 - 248
  • [3] Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
    Magbanua, Mark Jesus M.
    Sosa, Eduardo V.
    Scott, Janet H.
    Simko, Jeff
    Collins, Colin
    Pinkel, Dan
    Ryan, Charles J.
    Park, John W.
    BMC CANCER, 2012, 12
  • [4] New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
    Conteduca, Vincenza
    Mosca, Alessandra
    Brighi, Nicole
    de Giorgi, Ugo
    Rescigno, Pasquale
    CELLS, 2021, 10 (01) : 1 - 13
  • [5] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
  • [6] The changing landscape in the treatment of metastatic castration-resistant prostate cancer
    El-Amm, Joelle
    Aragon-Ching, Jeanny B.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2013, 5 (01) : 25 - 40
  • [7] Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer
    Galletti, Giuseppe
    Leach, Benjamin I.
    Lam, Linda
    Tagawa, Scott T.
    CANCER TREATMENT REVIEWS, 2017, 57 : 16 - 27
  • [8] New drugs in metastatic castration-resistant prostate cancer
    Albiges, L.
    Loriot, Y.
    Gross-Goupil, M.
    Rouge, T. de La Motte
    Blesius, A.
    Escudier, B.
    Massard, C.
    Fizazi, K.
    BULLETIN DU CANCER, 2010, 97 (01) : 149 - 159
  • [9] Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
    Mark Jesus M Magbanua
    Eduardo V Sosa
    Janet H Scott
    Jeff Simko
    Colin Collins
    Dan Pinkel
    Charles J Ryan
    John W Park
    BMC Cancer, 12
  • [10] PSMA theragnostics for metastatic castration resistant prostate cancer
    Song, Hong
    Guja, Kip E.
    Iagaru, Andrei
    TRANSLATIONAL ONCOLOGY, 2022, 22
12345